✓ Translated by DotMD AI Clinical Council Source: Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association • Phase III Randomized Trial
Verify Primary Source: NIH PubMed PMID #37106214 ↗

Phase III Randomized Trial: Body weight loss as a prognostic and predictive factor in previously treated patients with metastatic gastric cancer: post hoc analyses of the randomized phase III TAGS trial

Original Paper Title: “Body weight loss as a prognostic and predictive factor in previously treated patients with metastatic gastric cancer: post hoc analyses of the randomized phase III TAGS trial”

Elena Rostova (AI Quant) Rigor Score
88 / 100
Sample Size (Participants)
Systematic Review
Evidence Classification
Phase III Randomized Trial
Sarah Jenkins, RN (AI Plain-English Editor) • Key Takeaways
  • In TAGS, early BWL was a strong negative prognostic factor for OS in patients with mGC/GEJC receiving third- or later-line treatment.
  • Study Design & Sample: Phase III Randomized Trial published in Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association (Multi-cohort synthesis).
  • Biostatistical Rigor Score: 88/100 audited by Elena Rostova (AI Biostatistician & openFDA Quant).

What the Study Found (In Plain English)

Published in Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association (2023), this phase iii randomized trial evaluating human clinical outcomes investigated: Body weight loss (BWL) is a negative prognostic factor in metastatic gastric or gastroesophageal junction cancer (mGC/GEJC). Key clinical takeaway: In TAGS, early BWL was a strong negative prognostic factor for OS in patients with mGC/GEJC receiving third- or later-line treatment.

Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers

Primary Endpoint & Quantitative Summary (Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2023-07-15; Phase III Randomized Trial; Rigor 88/100): In TAGS, early BWL was a strong negative prognostic factor for OS in patients with mGC/GEJC receiving third- or later-line treatment.

Study Limitations & Caveats Before You Act

Clinical trials evaluate specific inclusion/exclusion cohorts under protocol-controlled conditions (Phase III Randomized Trial). Individual response, hepatic/renal clearance, CYP450 drug interactions, and baseline comorbidities vary; verify applicability with a board-certified physician before modifying any prescription or supplement regimen.

Related DotMD Clinical Hubs & Price Ledgers

Rx: trifluridine → Rx: trifluridine-and-tipiracil → Rx: stomach-relief-ultra-strength-bismuth-subsalicylate → Rx: stomach-relief-24-7-life-by-7-eleven-bismuth-subsalicylate-tablet → Condition: body-weight → Condition: cancer-living-with-cancer → Condition: cerebellar-disorders →
Transparent AI Research Council • Grounded on NIH / FDA / PubMed Data

Ask our AI Specialists anything about PMID 37106214: Phase III Randomized Trial: Body weight loss as a prognostic and predictive factor in previously treated patients with metastatic gastric cancer: post hoc analyses of the randomized phase III TAGS trial

3 of 3 Free Questions Remaining